Design Therapeutics Inc
DSGN
NASDAQ
Biotechnology
$14.83
USD
+0.44 (+3.06%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $900.55M
Volume 259.8K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-70.80M
TTM
-11.5%
YoY
Operating Cash Flow
$-55.08M
TTM
-8.8%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 5.8 | 4.7 | 4.7 | 5.3 | 5.8 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 21.6 | 19.3 | 18.2 | 19.7 | 22.2 |
Operating Income | -21.6 | -19.3 | -18.2 | -19.7 | -22.2 |
EBITDA | -21.4 | -19.2 | -18.0 | -19.5 | -22.0 |
Other Income / Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Other Income / Expense | 2.5 | 2.3 | 2.2 | 2.1 | 2.0 |
Income Before Income Taxes | -19.1 | -17.0 | -16.0 | -17.6 | -20.2 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -19.1 | -17.0 | -16.0 | -17.6 | -20.2 |
Consolidated Net Income / Loss | -19.1 | -17.0 | -16.0 | -17.6 | -20.2 |
Net Income Attributable to Common Shareholders | -19.1 | -17.0 | -16.0 | -17.6 | -20.2 |
Basic EPS | -$0.34 | -$0.30 | -$0.27 | -$0.29 | -$0.32 |
Diluted EPS | -$0.34 | -$0.30 | -$0.27 | -$0.29 | -$0.32 |
Basic Shares Outstanding | 56.9M | 57.0M | 58.8M | 61.4M | 62.5M |
Diluted Shares Outstanding | 56.9M | 57.0M | 58.8M | 61.4M | 62.5M |